Aignostics is an international, interdisciplinary company focused on powering the next generation of precision medicine by advancing AI and pathology. Founded in 2018 as a spin-off from Charité Berlin, one of Europe's largest and most esteemed university hospitals, they have grown to include a diverse team of experts across data science, machine learning, pathology, and biology. With offices in Berlin and New York, they leverage proprietary access to multimodal clinical datasets, leading AI technologies, and rigorous science to develop transformative insights for drug discovery, translational research, clinical trials, and companion diagnostic (CDx) development.

Their mission is to transform drug development and improve patient outcomes using AI that delivers novel insights for precision medicine. Their expertise encompasses multi-modal data from over 30 million patient samples from leading university hospitals and laboratories, deep biomedical knowledge, advanced machine learning capabilities including industry-leading foundation models, and research collaborations with top academic institutions in the EU and US. They provide a range of rigorously developed products and custom services spanning pathology foundation models, tumor microenvironment profiling, digital diagnostics, target and biomarker discovery, and translational research.